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Abstract: Catheter-associated urinary tract infections (CAUTIs) are among the leading nosocomial
infections in the world and have led to the extensive study of various strategies to prevent infection.
However, despite an abundance of anti-infection materials having been studied over the last forty-five
years, only a few types have come into clinical use, providing an insignificant reduction in CAUTIs.
In recent decades, marine resources have emerged as an unexplored area of opportunity offering huge
potential in discovering novel bioactive materials to combat human diseases. Some of these materials,
such as antimicrobial compounds and biosurfactants synthesized by marine microorganisms, exhibit
potent antimicrobial, antiadhesive and antibiofilm activity against a broad spectrum of uropathogens
(including multidrug-resistant pathogens) that could be potentially used in urinary catheters to
eradicate CAUTIs. This paper summarizes information on the most relevant materials that have been
obtained from marine-derived microorganisms over the last decade and discusses their potential as
new agents against CAUTIs, providing a prospective proposal for researchers.
Keywords: marine microorganisms; urinary catheter; antibiofilm; antifouling; coating
1. Introduction
Urinary catheters are hollow, partially flexible tubes that are designed to drain urine
from the bladder. The earliest use of urinary catheters can be traced back to the third
century B.C., but the modern indwelling catheter, called the ‘Foley’ catheter, was designed
by Frederick B. Foley in the mid-1930s [1]. To date, over 100 million urinary catheters are
used worldwide per year since catheterization rates remain high at 20% in non-intensive
care units and 61% in intensive care units (ICUs) [2]. Despite the care taken to avoid
contamination, catheters are still susceptible to infections as they provide direct access for
uropathogens from the outside environment into the urinary tract, impairing local host
defence mechanisms of the bladder [3,4]. Opportunistic uropathogens (Table 1) are mainly
faecal or skin microbiota from the patients that can enter the bladder through the catheter
lumen (34%) or along the catheter–urethral interface (66%) causing infections and compli-
cations, such as encrustation, bladder stones, bacteriuria, pyelonephritis, septicaemia and
endotoxic shock (Figure 1) [3,5–7]. According to the European Centre for Disease Preven-
tion and Control (ECDC), catheter-associated urinary tract infections (CAUTIs) account for
27% of all hospital-acquired infections in developed countries, and over 1 million cases
occur in the USA and Europe [1,8]. In the UK, CAUTIs cost the NHS GBP 1–2.5 billion and
account for approximately 2100 deaths annually [9].
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i re 1. at ical cr ss-secti of the renal syste in a ale sho ing CAUTIs.
Depending on clinical indications, the duration of catheterization may be short-
(<7 days) or long-term (>28 days). Early work showed that 10–50% of patients undergoing
short-term catheterization developed bacteriuria, and all patients undergoing long-term
catheterization became infected, regardless of whether the catheter system was open or
closed [10]. As a basic survival strategy, teria that encounter a catheter surface sub-
merged i urine become attached within min tes [11]. These attached bacteria begin
to phenotypically change, producing extracellular polymeric substances (EPS) (mainly
exopolysaccharides and proteins) that allow the emerging biofilm community to develop
a complex, three-dimensional structure within hours. Once established, the biofilms are
very difficult to eradicate and exhibit a high tolerance to antibiotics and other biocidal
treatments, making them a continuous focus for infections that can only be eliminated by
the constant removal of the catheters [3,7,12–15]. Furthermore, in the presence of urease-
positive bacteria (e.g., Proteus mirabilis), urease catalyses the hydrolysis of urea into carbon
dioxide and ammonia, which increases the urine pH, leading to the precipitation of calcium
and magnesium phosphate crystals (encrustation) and the formation of crystalline biofilms
on the catheter, which eventually results in the complete blockage of the catheter [7,16,17].
Previous attempts to prevent CAUTIs include improving sterile techniques to inhibit the ac-
cess of microbes into the urinary tract and limiting microbial accumulation on the catheter
surface by intermittent catheterization. However, clinical evidence shows that these efforts
do not lead to a noticeable reduction in CAUTIs [15]. Therefore, developing novel urinary
catheters with antibiofilm and antiencrustation properties remains the most direct and
promising strategy for this significant clinical problem.
Table 1. Common pathogens causing CAUTI.
Short-Term Catheterization Type References
Escherichia coli GN bacterium [18]
Serratia spp. GN bacterium [19]
Staphylococcus epidermidis GP bacterium [20]
Enterococcus spp. GP bacterium [21]
Bacillus subtilis GP bacterium [3]
Long-Term Catheterization Type References
Providencia aeruginosa GN bacterium [1]
Proteus mirabilis GN bacterium [7]
Providencia stuartii GN bacterium [22]
Morganella morganii GN bacterium [6]
Klebsiella pneumoniae GN bacterium [23]
Staphylococcus aureus GP bacterium [24]
Candida spp. Fungus [25]
GN: Gram-negative; GP: Gram-positive.
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2. Current Anti-Infection Strategies against CAUTIs and Challenges
Current commercial urinary catheters can be generally classified as standard and
antimicrobial catheters (Figure 2). Owing to their superior malleability, several materials
used for making standard catheters include polyvinyl chloride (PVC), polyurethane (PU),
silicone and latex [20]. Of these, silicone has emerged as the material of choice for urinary
catheters due to distinct advantages, including excellent biocompatibility, no allergic
reactions, superior chemical and thermal stability and good mechanical strength [2,26].
Morris et al. [27] compared the antiencrustation performance of 18 types of catheter and
found that all-silicone urinary catheters took the longest time to encrust and block. The
main reason for this lies in that the all-silicone catheter has a wider lumen, allowing a
faster urine flow, which prevents the accumulation of crystalline deposits. However, recent
studies demonstrated that there was no significant difference between the development
of infections or bacterial adherence on silicone catheters as compared to other types of
catheters [20,26,28,29].
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resistance among uropathogens that can render these antibiotics useless after repeated 
applications. Therefore, the identification of new resources for novel antibiotics with new 
modes of action has become the research focus over the past two decades. Currently, over 
75% of the antibiotics currently available on the market are derived from terrestrial organ-
isms, and the discovery of new antibiotics has declined considerably (only two new clas-
ses of antibiotics have been commercialized since 1962) due to difficulties in identifying 
novel and effective compounds [45–47].  
Oceans cover 71% of the Earth’s surface, but less than 5% have been explored to date, 
presenting an unexplored area of opportunity [48,49]. In recent decades, significant pro-
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tif li t ri ls f r t e revention of TIs.
Given that bacterial adhesion is the critical step in the progression of biofilm for-
mation, numerous attempts have been made to endow the catheters with antiadhesive
or antimicrobial properties, or both. Antiadhesive coatings are designed to prevent mi-
crobial adhesion through mechanisms of steric repulsion, electrostatic repulsion or low
surface energy instead of killing the microbes [15]. To date, hydrogel- and polytetrafluo-
roethylene (PTFE)-coated catheters are commercially available, but clinical studies demon-
strate that their efficacies against CAUTI are insignificant when compared with standard
catheters [2,4,26,30]. Despite their lubricating features that may help improve patient
comfort, hydrogel- or PTFE-coated catheters are only suitable for short- or medium-term
catheterization (<28 days). Antimicrobial coatings are characterized by bactericidal or
bacteriostatic activities that protect the catheters from microbial adhesion and migration.
Recent reviews of commercial antimicrobial catheters identified two main strategies used:
silver-based coatings and antibiotic impregnation [1,7,31]. However, all these catheters
have only been reported to yield positive results for short-term application [7,20,32].
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Silver is among the few FDA-approved antimicrobial materials for urinary catheter
coatings, and its antimicrobial activity is associated with the release of silver ions. To
date, silver has been applied in catheter coatings in the forms of bulk silver, silver al-
loy (silver/gold or palladium) and silver-hydrogels. Silver is very prone to oxidation in
aqueous conditions, and the release of silver ions from these coatings often undergoes an
initial burst-release phase followed by a slow-release phase. In clinical trials, the long-term
antimicrobial efficacy of these silver-based coatings has proven limited [1,28,33]. In this sce-
nario, attempts have been made to introduce silver nanoparticles into catheter coatings to
attain enhanced antimicrobial efficacy. However, concerns have also been raised about the
potential toxicity towards patients due to the fast and excessive release of silver ions [33,34].
In comparison, despite studies suggesting that the overuse of antibiotics may result in the
development of antibiotic resistance, certain types of antibiotic-impregnated catheters have
been proven to be more effective than silver-based antimicrobial catheters in preventing
CAUTIs [3,20,35–37]. For example, nitrofurazone-impregnated catheters are commercially
available, and studies comparing silver-alloy coated catheters, silver-hydrogel coated
catheters, and nitrofurazone-impregnated catheters have found that nitrofurazone could
effectively reduce the risk of symptomatic CAUTI and bacteriuria in short-term catheteriza-
tion by impairing bacterial adherence and planktonic growth, while silver-based catheters
have only demonstrated minimal effects [28,38]. Pickard et al. [33] compared the ability
of silver-alloy-coated catheters and nitrofural-impregnated catheters for the reduction in
incidence of symptomatic CAUTIs in adults requiring short-term catheterization via a
clinical model, and the results demonstrated that nitrofural-impregnated catheters were
more effective than the silver-alloy-coated catheters. In addition, impregnating antibiotics
into catheters provides a cost-effective strategy to manufacture antimicrobial catheters,
as this can be achieved by simply submerging swollen catheters in antibiotic-containing
solutions for antibiotic encapsulation [31]. However, there are still certain concerns about
using nitrofurazone in urinary catheters, such as patient discomfort [38] and the potential
risks of developing tumours [39] and resistance in bacteria. This has hindered research in
this field, and there is a growing demand for developing new antibiotics instead.
Apart from silver and antibiotics, recent research has also focused on a variety of an-
tifouling materials (e.g., poly(ethylene glycol) (PEG) and polyzwitterions) [2,40] and biocidal
materials (e.g., nitric oxide, antimicrobial peptides, enzymes and bacteriophages) [41–44]
for urinary catheter coatings and has reported with varying levels of success, which offers
potential for complete protection against CAUTIs. However, the promising performance
of anti-infection coatings under laboratory conditions has not been translated into clinical
success to date. Therefore, exploring novel anti-infection materials for urinary catheters
will remain a current and broad interest in the upcoming decade.
3. Marine Microbiota as a Source of Novel Anti-Infection Materials
For short-term urinary catheters, the use of antibiotics has proven to be a cost-efficient
strategy to prevent CAUTIs in clinical trials, but a major concern is the development of
antibiotic resistance, particularly the increasing emergence of new forms of multidrug
resistance among uropathogens that can render these antibiotics useless after repeated
applications. Therefore, the identification of new resources for novel antibiotics with new
modes of action has become the research focus over the past two decades. Currently,
over 75% of the antibiotics currently available on the market are derived from terrestrial
organisms, and the discovery of new antibiotics has declined considerably (only two new
classes of antibiotics have been commercialized since 1962) due to difficulties in identifying
novel and effective compounds [45–47].
Oceans cover 71% of the Earth’s surface, but less than 5% have been explored to
date, presenting an unexplored area of opportunity [48,49]. In recent decades, significant
progress in the clinical development of marine-derived drugs has been achieved, and the
discovery of novel antimicrobial substances from marine organisms has indicated their
potential to combat existing medical device-related infections [50–54]. However, there are
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concerns that the overexploration of marine organisms may affect the balance between
ecological constraints and economic activity. In this scenario, marine microbiota are emerg-
ing as a viable source of bioactive materials [55]. Diverse marine habitats provide unique
conditions for marine microorganisms to develop into complex and diverse assemblages,
and the isolation and extraction of bioactive secondary metabolites from such organisms
are relevant to the discovery of novel anti-infection agents [56–59]. Therefore, microbes
isolated from previously unexplored marine habitats may lead to the discovery of novel
structures with potent antibiotic activity, and marine microbial-derived antibiotics are
believed to be a promising alternative to overcome existing problems [60–62].
For long-term catheters, microbes are more prone to colonize and build biofilms on the
surfaces with the attenuation of antimicrobial efficacy. Catheters with only biocidal activity
are considered insufficient to eradicate CATUIs, as recent studies demonstrated that a
’foundation layer’ composed of both dead and live bacteria can form on the catheter surface
in long-term catheterization, which protects bacteria from contact with underlying biocidal
substances [4,63]. To solve this problem, more research has focused on endowing catheter
surfaces with both biocidal and antiadhesion properties [4,9,15,64]. Biosurfactants (BSs)
are amphipathic secondary metabolites produced by microorganisms and have become
a promising anti-infection material for medical applications [65–67]. Recent studies of
the anti-infection functions of biosurfactants have identified three main routes, including
killing microbes or inhibiting microbial growth, resisting microbial adhesion and disrupt-
ing biofilm formation [68–70]. For example, several BSs isolated from terrestrial-derived
microbes, such as surfactin [71] and iturin [72], display potent antimicrobial activities,
which make them relevant molecules in combating infections. Van Hoogmoed et al. [73]
reported that biosurfactants released by Streptococcus thermophilus significantly inhibited
Candida spp. adhesion to silicone rubber, which indicates their potential for use as a defence
against colonizing strains on urinary catheters. These biosurfactants are mostly obtained
from terrestrial-derived microorganisms, while biosurfactants produced by marine mi-
croorganisms have been less explored. Over the last decade, marine microbial-derived
biosurfactants have attracted increasing interest, as marine microbes may exhibit unique
metabolic and physiological capabilities producing novel metabolites with potent biological
activities. To date, a considerable number of marine microbial-derived biosurfactants with
antimicrobial, antiadhesive and antibiofilm activities have been obtained, and several have
been proven to be effective against a broad spectrum of uropathogens, including Gram-
positive and Gram-negative bacteria, as well as the yeast Candida albicans, which could
potentially offer a new solution to the problems associated with long-term catheterization.
In this review, we summarize the diversity of marine microbial-derived antibiotics
and biosurfactants discovered over the past 10 years and discuss their potential for use in
combatting CAUTIs in short-term and long-term urinary catheters.
4. Marine Microbial-Derived Antibiotics with Broad-Spectrum Antimicrobial Activity
Antibiotics are low-molecular-weight compounds produced by microorganisms that
kill or inhibit the growth of other microorganisms at low concentrations [74]. The current
understanding of the biological activity of antibiotics is mainly cantered on their primary
cellular targets. The mechanisms of antibiotic action can be classified into 5 categories:
(1) inhibition of cell wall synthesis (the most common mechanism), (2) inhibition of protein
synthesis, (3) alteration of cell membranes, (4) inhibition of nucleic acid synthesis and
(5) antimetabolite activity [75,76]. However, not all antibiotics have broad-spectrum an-
timicrobial activity, and their efficiency decays along with catheterization due to a limited
shelf-life. Some microbes may be inherently resistant to certain antibiotics, while they may
also mutate and/or exchange genetic material with other microbes, leading to the develop-
ment of multidrug resistance [77,78]. Furthermore, some antibiotics may exhibit toxicity at
or close to their therapeutic dose [47]. Considering the diversity of uropathogen species, the
ideal antibiotic for urinary catheters should exhibit broad-spectrum antimicrobial activity
and avoid developing resistance without inducing cytotoxicity in patients.
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Generally, antibiotic compounds based on their structures and/or biosynthetic ori-
gins can be classified as alkaloids [79], quinones [80], phenols [81], polyketides [82], ter-
penes [83], polyketides [84,85] and peptides [86]. Table 2 lists the recent discoveries of
marine microbial-derived compounds with broad-spectrum antimicrobial activity. Al-
though very few of them have been developed into clinical trial phases, several have
demonstrated to be effective against a broad spectrum of uropathogens, including Gram-
positive and Gram-negative bacteria, fungi, as well as methicillin-resistant Staphylococcus
aureus (MRSA). Therefore, they could be an alternative to conventional antibiotics for
short-term catheters against CAUTIs caused by those pathogens.
Over the last two decades, the most studied group of microbes producing antimicrobial
substances is the Firmicutes phylum (particularly the genus Bacillus) [87]. Tareq et al. [88–91]
reported the discovery of four types of bioactive molecules with broad-spectrum antimi-
crobial activity against both Gram-positive and Gram-negative bacteria and fungi. Gageo-
statins A–C (Figure 3a) and gageopeptides A–D (Figure 3b) are two types of non-cytotoxic
linear lipopeptides isolated from a marine Bacillus subtilis 109GGC020. The authors pro-
posed a biosynthetic pathway based on nonribosomal peptide synthetases (NRPS) for the
production of gageotetrins. Comparative studies showed that gageostatins A–C were more
active against fungi than bacteria with minimum inhibitory concentration (MIC) values of
0.02–0.04 µM. Gageopeptides A–D exhibited potent antifungal and moderately broad an-
tibacterial activity, while not showing cytotoxicity to human myeloid leukaemia K-562 and
mouse leukemic macrophage RAW 264.7 cell lines. Gageomacrolactins A–C (Figure 3c) are
three macrolactin derivatives obtained from the secondary metabolites of marine Bacillus
subtilis 109GGC020 and displayed strong broad-spectrum activity against Gram-negative
and Gram-positive bacteria and fungi. By comparing the structure-function of the gageo-
macrolactins A–C with that of known macrolactins 4–7, the authors demonstrated that
antibacterial activity was not affected by the position of the epoxide group but highly
dependent on the hydroxyl group at C-15 of the macrolactone ring. Ieodoglucomides 1 and
2 (Figure 3d) are two unique glycolipopeptides produced by a marine Bacillus licheniformis
09IDYM23 which act as moderate antimicrobial molecules. Podilapu et al. [92] reported
the successful synthesis of ieodoglucomides A and B through a high-yielding route using
per-O-TMS glucosyl iodide, making them promising candidates for industrial application.
Apart from Bacillus spp., Uzair et al. [93] reported the isolation of 4-[(Z)-2 phenyl
ethenyl] benzoic acid (kocumarin) from the marine Kocuria marina CMG S2, which ex-
hibited pronounced and rapid growth inhibition against fungi and pathogenic bacteria,
including methicillin-resistant Staphylococcus aureus (MRSA). Although its antimicrobial
mechanism has not been clearly elucidated, research on the functional groups involved in
the molecular mechanism would reveal further insights into this atypical class of antibi-
otics. Schumacher et al. [84] described the first antimicrobial polyketide (bonactin) isolated
from the liquid culture of a Streptomyces sp. BD21-2, a compound displaying antifungal
and broad-spectrum antibacterial activity against microbes, including Bacillus megaterium,
Micrococcus luteus, Klebsiella pneumoniae, Staphylococcus aureus, Alcaligenes faecalis, Escherichia
coli and Saccharomyces cerevisiae. However, such marine microbial-derived compounds with
activity against both bacteria and fungi are still very rare to date.
Over the past 10 years, numerous molecules possessing broad-spectrum antibacterial or
antifungal activities have been isolated from marine microorganisms. Glycosylated macro-
lactins A1 and B1 (Figure 3e) were isolated from a marine Streptomyces sp. KJ371985, which
inhibited Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus
with MICs of 0.03–0.22 µM. These compounds inhibit the peptidyl transferase activity and
binding of the acceptor substrate to bacterial ribosomes. The higher solubility in the polar
solvents of sugar-containing macrolactins could be an advantage in clinical applications [94].
Bacteriocins are natural peptides synthesized by bacteria for the purpose of killing/inhibiting
other bacterial strains whilst not harming the producing bacteria through specific immunity
proteins [95]. Elayaraja et al. [96] purified a bacteriocin from marine Lactobacillus murinus
AU06, which exhibited a broad inhibitory spectrum against both Gram-positive and -negative
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bacteria. Marinocine is a broad-spectrum antibacterial protein synthesized by the melanogenic
marine bacterium Marinomonas mediterranea, which generates hydrogen peroxide that kills
bacteria [97]. However, recent studies demonstrated that the molecular basis of the antibacte-
rial activity was L-lysine dependent, and activity was inhibited under anaerobic conditions.
Mollemycin A (Figure 3f) is an antibacterial glyco-hexadepsipeptide-polyketide isolated from
an Australian marine-derived Streptomyces sp. (CMB-M0244), which exhibited exceptionally
potent and selective growth inhibitory activity against Gram-positive and Gram-negative
bacteria (IC50 10–50 nM) but did not show any antifungal activity against Candida albicans.
The cytotoxicity test also showed that mollemycin A was proportionately less cytotoxic
toward human neonatal foreskin fibroblast cells [98]. Thiomarinols A–G (Figure 3g) were
discovered as a class of polyketide antibiotics from marine Alteromonas rava SANK 73390,
which displayed broad-spectrum activity against Gram-positive and Gram-negative bacterial
species [99]. These thiomarinols act through inhibiting bacterial isoleucyl-transfer RNA syn-
thetase and have pronounced activity against MRSA, with MICs ≤ 0.01 µg/mL [60]. Similar
antibacterial compounds were also obtained from actinobacteria, such as Pseudonocardia car-
boxydivorans M-227 [100] and Streptomyces sp. JRG-04 [101]. Fungi (primarily Candida species)
account for 20–30% of CAUTI cases, and Candida albicans is the most prevalent pathogen
found in CAUTI biofilms [1,37]. Antifungal (particularly anti-Candida) compounds derived
from marine microbes have been reported for metabolites produced by Streptomyces sp.
ZZ338 [102], Streptomyces sp. SNM55 [103], Bacillus subtilis KC433737 [104], Janthinobacterium
spp. ZZ145 and ZZ148 [105], Trichoderma sp. MF106 [106] and Stagonosporopsis cucurbitacearum-
strain G019 [107]. These microbial strains, respectively produced actinomycins D, V and X0β
(Figure 4a) (MIC, 9.83–9.96 µM); mohangamides A and B (Figure 4b) (IC50, 4.4 and 20.5 µM);
5-hydroxymethyl-2-furaldehyde (5HM2F) (Figure 4c) (MBIC, 400 µg/mL); janthinopolyene-
mycin A and B (Figure 4d) (MIC, 15.6 µg/ML, MBC, 31.25 µg/mL); trichodin A (Figure 4e)
(IC50, 25.38 ± 0.41 µM); and didymellamide A (Figure 4f) (MIC, 3.1 µg/mL).
Table 2. Marine microbial-derived compounds with broad-spectrum antimicrobial activity.
Compound Molecular Class Source Target Reference
Gageotetrins A–C Peptide Bacillus subtillis 109GGC020 B/F [90]
Gageopeptides A–D Peptide Bacillus subtillis 109GGC020 B/F [91]
Ieodoglucomide 1, 2 Peptide Bacillus licheniformis 09IDYM23 B/F [88]
Bacteriocin Peptide Lactobacillus murinus AU06 B [96]
Actinomycins D, V, X0β Peptide Streptomyces sp. ZZ338 F [102]
Mohangamides A, B Peptide Streptomyces sp. SNM55 F [103]
Gageomacrolactins A–C Macrolide Bacillus subtillis 109GGC020 B/F [89]
Glycosylated macrolactins A1, B1 Macrolide Streptomyces sp. (KJ371985) B [94]
Bonactin Acyclic ester Streptomyces sp. BD21-2 B/F [86]
Butenolide Lactone Streptomyces sp. B [108]
Mollemycin A Peptide-polyketide Streptomyces sp. CMB-M0244 B [98]
Thiomarinols A-G Polyketide Alteromonas rava SANK 73390 B [99]
Branimycin B, C Polyketide Pseudonocardia carboxydivorans M-227 B [100]
UN Polyketide Streptomyces sp. JRG-04 B [101]
Janthinopolyenemycin A, B Polyketide Janthinobacterium spp. ZZ145 and ZZ148 F [105]
Kocumarin Benzoic acid Kocuria marina CMG S2 B/F [93]
Marinocine Protein Marinomonas mediterranea MMB-1 B [109]
5HM2F Furan Bacillus subtilis KC433737 F [104]
Trichodin A Pyridone Trichoderma sp. MF106 F [106]
B: Gram-positive and Gram-negative bacteria; F: fungi; UN: unnamed material.
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5. Marine Microbial-Derived Biosurfactants: New Agents against CAUTIs
Biosurfactants (BSs) are amphipathic secondary metabolites produced by microor-
ganisms that consist of both hydrophilic and hydrophobic moieties [45]. Compared to
conventional chemical surfactants, these biomolecules have many advantages, such as
low toxicity; high biodegradability; biocompatibility; low critical micelle concentrations
(CMC); an ability to function over wide ranges of pH, temperature and salinity; as well
as great r selectivity, and can be produced from renewable, cheaper substrates [110,111].
Such characteristics allow BSs to play a key role in multidisciplinary applications in in-
dustrial and environmental fields and make them a green alternative to their chemical
counterparts. Furthermore, some BSs have been reported for their specific bioactivities,
which play an essential role in the survival of microbial producers against other competing
microbes [69,112]. In nature, BSs can be secreted extracellularly or remain attached to cell
surfaces, reducing surface tension at the interface, thereby reducing surface contamination
and aiding microbial motility in potentially hostile environments [113]. BSs may also have
a range of therapeutic and biomedical benefits and could be used instead of conventional
antibiotics to combat infections [114]. Current research regarding BSs has mostly focused
on microbes from terrestrial sources (particularly soil-isolated microbes such as species of
Bacillus, Pseudomonas and yeasts) [45,112], while practical applications of BSs in healthcare
are still limited [115]. For this reason, marine habitats have again emerged as a potential
source for isolating new BSs, and the discovery of new BS-producing microorganisms is
attracting increasing interest.
BSs according to t eir molecular weight can be grouped into two categories: (a)
high-molecular-mass (HMW) molecules ( lso called bioemulsifiers), such as polysaccha-
rides, proteins, lipopolysaccharides, lipoproteins and lipoheteropolysaccharides, and (b)
low-molecular-mass (LWM) molecules (generally 500 to 1500 Da), which can be further
subdivided into glycolipids, lipopeptides, phospholipids, polymeric compounds and neu-
tral lipids based on their chemical composition and microbial origin [45,65,116]. Recent
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research has mainly focused on the LWM BSs, and several have been reported to dis-
play antimicrobial, antiadhesive and antibiofilm activities against a broad spectrum of
uropathogens (including multidrug-resistant pathogens), indicating their use as promising
anti-infection materials for urinary catheters (Table 3).
5.1. Antimicrobial Activity
Biosurfactants have been reported to exhibit antimicrobial activity via different mech-
anisms of action, which primarily destroy the cell wall or plasma membrane by disrupting
their integrity and permeability [65,68,117,118]. More specifically, their amphiphilic charac-
teristics and affinity for lipid bilayers allow BSs to interact with cell membranes, leading
to cell lysis and metabolite leakage, which ultimately results in cell death [116]. To date,
various marine microbes have been reported to produce antimicrobial BSs, of which glycol-
ipids and lipopeptides are the two primary isolated families that display broad-spectrum
antimicrobial activity.
Glycolipids are a class of carbohydrate molecules made of mono-, di-, tri- and tetra-
saccharides in combination with long-chain aliphatic acids or hydroxyaliphatic acids [119],
of which trehalolipids, rhamnolipids and sophorolipids are of the most interest [120]. Re-
ported marine microbial-derived glycolipid BSs with broad-spectrum antimicrobial activity
against both bacteria and fungi are listed in Table 3. A glycolipid BS isolated from a marine
Staphylococcus saprophyticus SBPS 15 exhibited dual functions: (1) excellent antibacterial
and antifungal activities against a broad spectrum of clinical human pathogens, including
Gram-positive bacteria (Bacillus subtilis and Staphylococcus aureus), Gram-negative bacteria
(Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae and Salmonella paratyphi) and
fungi (Aspergillus niger, Candida albicans and Cryptococcus neoformans), and (2) potent surface
tension-reducing activity (32 mN/m). This BS also showed superior stability over a broad
range of pH (3–9) and temperature (up to 80 ◦C) [121]. Another glycolipid BS purified
from extracts of a tropical marine strain of Serratia marcescens demonstrated similar dual
functions, inhibiting the growth of Candida albicans and Pseudomonas aeruginosa with MIC
values of >25.0 µg/mL and preventing adhesion by up to 99% [122]. The glycolipid BS
also displayed biofilm disrupting activities against the test strains, which were believed
to result from synergistic antimicrobial and surfactant activity. Glycolipid BSs were also
isolated from the marine actinobacteria Brevibacterium casei MSA19, Streptomyces sp. MAB36
and Brachybacterium paraconglomeratum MSA21. The MSA19 glycolipid was bacteriostatic
and could inhibit microbial attachment and disrupt both fungal and bacterial biofilms
in both individual strains and mixed cultures at 30 µg/mL [123]. The MAB36 glycolipid
also possessed strong antimicrobial activity against pathogenic bacteria and fungi and
demonstrated excellent stability over a wide range of pH, temperature and ion concentra-
tions [124]. The BS produced by the sponge-associated Brachybacterium paraconglomeratum
MSA21 displayed broad antibiotic activity and it was suggested that the discovery of
polyketide synthase (pks II) genes might pave the way for making new BSs by exploiting
the microbial genes and enzymes, making the green production of BSs possible in the
future [125]. Another glycolipid BS was isolated from a marine halotolerant bacterium
(Buttiauxella sp. M44) that exhibited significant stability over a broad range of pH (7–8),
temperature (20–60 ◦C) and salinity (0–3%) and potent antimicrobial activity against both
bacteria and fungi [126]. Moreover, the combination of a cheap energy and carbon source
(e.g., molasses) as well as a response surface method (RSM) could favor production and
expand possible uses in the future.
Lipopeptides (LPs) are composed of peptide chains (short linear or cyclic structures)
with lipid moieties and are the most widely reported class of biosurfactants with an-
timicrobial activity. Bacillus species are the most studied LP-producing strains that have
been reported to produce several antimicrobial lipopeptide biosurfactants (LPBs), such as
surfactin, iturin and fengycin, although most of these strains are from terrestrial ecosys-
tems [70,72]. Liu et al. [71] reported the first surfactin (mainly composed of the nC14-
and anteiso-C15-surfactin) isolated from marine Bacillus velezensis H3, which exhibited
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antimicrobial activity against a broad range of pathogens, including Staphyloccocus aureus,
Klebsiella peneumoniae, Pseudomonas aeruginosa and Candida albicans. The surfactin demon-
strated a lower inhibitory effect than the antibiotic polymixin B but greater antifungal
activity against Candida albicans than the antibiotic vancomycin. Similar antibacterial and
antifungal activities were also found for the BSs produced by Halobacterium salinarum [127].
Another surfactin produced by the marine actinobacterium Nocardiopsis alba MSA10 was
shown to effectively inhibit the growth of Enterococcus faecalis, Klebsiella pneumoniae, Micro-
coccus luteus, Proteus mirabilis, Staphylococcus aureus, Staphylococcus epidermidis and Candida
albicans, however, without effects on Escherichia coli and Pseudomonas aeruginosa [128]. Apart
from surfactin, Balan et al. [129] first reported the discovery of aneurinifactin from the
marine Aneurinibacillus aneurinilyticus SBP-11, which showed broad-spectrum antibacterial
activity against Klebsiella pneumoniae, Escherichia coli, Staphylococcus aureus, Pseudomonas
aeruginosa, Bacillus subtilis and Vibrio cholerae. The antibacterial mechanism was proposed
to be derived from the anchoring of the BS on the bacterial cell membrane that disrupted its
integrity, resulting in the production of hydroxyl radicals, which in turn caused lipid perox-
idation and pore formation in the membrane [129]. However, antifungal activity was not
investigated. It was also reported that a LPB (pontifactin) produced by marine Pontibacter
korlensis SBK-47 displayed high antibacterial activity against Streptococcus mutans, Micro-
coccus luteus, Salmonella typhi and Klebsiella oxytoca and moderate activity against Klebsiella
pneumonia and Vibrio cholerae. The molecule also showed antiadhesion potential against
Bacillus subtilis, Staphylococcus aureus, Salmonella typhi and Vibrio cholerae [130]. Lawrance
et al. [131] discovered an antibacterial LPB from the marine sponge-associated bacterium
Bacillus licheniformis NIOT-AMKV06, which displayed significant bacteriostatic activity
against a range of human pathogens, including Enterococcus faecalis, Klebsiella pneumoniae,
Micrococcus luteus, Proteus mirabilis, Salmonella typhi, Shigella flexneri, Staphylococcus aureus
and Vibrio cholerae. The production of these biosurfactants in heterologous host strains
was achieved by cloning three gene clusters (sfp, sfpO and srfA) in Escherichia coli, with
production being increased three-fold over the original strain. In addition, a lipopep-
tide BS produced by the marine Bacillus circulans is the only one found to be effective
against multidrug-resistant (MDR) clinical strains while not having any haemolytic activity,
indicating its potential to combat infections caused by such pathogens [132].
5.2. Antiadhesive and Antibiofilm Activities
Biosurfactants have also been reported to inhibit microbial adhesion and biofilm
formation without exerting antimicrobial activity [69,133,134]. Despite the precise mecha-
nisms of such activity not being fully understood, biosurfactants may affect interactions
between microbes and surfaces through several modes of action: (1) modification of the
physico-chemical properties (e.g., surface charge, hydrophobicity and surface energy) of
the surface, which reduces microbial adhesion [111]; (2) suppression of the expression
of biofilm-related genes, which inhibits microbial adhesion [135]; (3) promotion of the
solubilization of biofilms encouraging bacterial detachment [136]; and (4) the interference
of quorum sensing leading to decreased biofilm formation [70]. Numerous studies have
shown that the prior adhesion of BSs to catheter surfaces (surface conditioning) reduced
microbial adhesion and colonization [137–139].
In general, bacterial adhesion to a surface is regulated by diverse factors (e.g., growth
medium, substrate and cell surface). The most frequently cited theory is the two-step adhe-
sion model in which the adhesion process is divided into two distinct phases: reversible
adhesion and irreversible adhesion [11,12,140]. Reversible adhesion describes a dynamic
process in which bacteria can easily attach to or detach from a surface due to a combina-
tion of surface–cell interactions including van der Waals, electrostatic double-layer, Lewis
acid-base, Brownian motion and hydrophobic interactions [64,141]. Walencka et al. [142] re-
ported that BSs can affect cell-to-surface interactions by altering surface tension and charge
to overcome the initial electrostatic repulsion barrier. For instance, Meylheuc et al. [143] re-
ported that a stainless-steel surface coated with the BS produced by Pseudomonas fluorescens
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significantly reduced microbial adhesion. The presence of BS in the conditioned surface
remarkably reduced the surface energy and enhanced surface hydrophilicity, leading to
a decrease in attraction due to a reduction in the van der Waals forces and an increase in
electron–donor/electron–acceptor characteristics. Jemil et al. [144] also reported that elec-
trostatic repulsion between negatively charged surfaces (coated with anionic lipopeptides)
and the negatively charged microbial surface could aid in inhibiting microbial adhesion.
However, following reversible adhesion, microbial attachment gradually becomes stronger
with time through a range of interfacial rearrangements (e.g., removal of interfacial water,
protein conformational changes and an increase in hydrophobic interactions) and the pro-
duction of adhesins, eventually form biofilms [145]. Despite numerous studies highlighting
the difficulties in eliminating biofilms, BSs have been shown to disrupt or remove biofilms
by penetrating and absorbing at the interface between the solid substrate and the biofilm,
thereby reducing interfacial tension [134,146].
Antiadhesive and antibiofilm activities have also been reported for marine microbial-
derived BSs. Hamza et al. [134] reported a non-toxic glycolipid BS (SLSZ2) derived from
a marine epizootic bacterium Staphylococcus lentus SZ2 that effectively prevented the
adhesion of Vibrio harveyi and Pseudomonas aeruginosa without showing bactericidal activity.
In addition, this BS efficiently inhibited biofilm formation and disrupted the pre-formed
biofilms of both strains by ~80%. Another glycolipid BS produced from a marine Symphylia
sp. also exhibited antiadhesive activity against a range of pathogens (Candida albicans,
Pseudomonas aeruginosa and Bacillus pumilus) and could disrupt pre-formed biofilms of these
cultures in a concentration-dependent manner [122]. Similarly, a glycolipid BS isolated
from the marine actinobacterium Brevibacterium casei MSA19 disrupted biofilm formation
in Escherichia coli, Pseudomonas aeruginosa and Vibrio spp. under dynamic conditions.
Moreover, biofilm disruption activity was consistent against mixed and individual biofilm
bacteria at ~30 µg/mL. The lipopeptide BS produced by marine Bacillus circulans exhibited
promising antiadhesive activity against several potential pathogenic strains, and the BS-
coated surface effectively reduced microbial adhesion by up to 89% at a concentration of
0.1 g/L. Moreover, the pre-formed biofilms were removed with efficiencies between 59 and
94% for all the strains tested, demonstrating its potential in biomedical applications [147].
Song et al. [148] reported a lipopeptide BS produced by marine Bacillus amyloliquefaciens
anti-CA that inhibited biofilm formation and dispersed pre-formed biofilms of Pseudomonas
aeruginosa PAO1 and Bacillus cereus. The obtained data indicated that the BS could suppress
the expression of the PslC gene which is associated with exopolysaccharide production
in Pseudomonas aeruginosa PAO1. Pradhan et al. [149] also reported a lipopeptide BS
produced by a marine Bacillus tequilensis CH which effectively inhibited pathogenic biofilms
(Escherichia coli and Streptococcus mutans) on both hydrophilic and hydrophobic surfaces at
a concentration of 50 µg/mL.
Table 3. Marine microbial-derived BSs with antimicrobial, antiadhesive or antibiofilm activities.
Source Type Activity Reference
Staphylococcus saprophyticus SBPS 15 Glycolipid
Antibacterial activity against Klebsiella Pneumoniae, Escherichia
coli, Pseudomonas aeruginosa, Bacillus subtilis, Salmonella paratyphi
and Staphylococcus aureus




Antibacterial activity against Pseudomonas aeruginosa and
Bacillus pumilus
Antifungal activity against Candida albicans
Antiadhesive activity against Pseudomonas aeruginosa, Bacillus
pumilus and Candida albicans
[122]
Brevibacterium casei MSA19 Glycolipid
Antibacterial activity against Escherichia coli, Klebsiella
pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Vibrio
parahaemolyticus and Vibrio vulnificus
Antibiofilm activity against mixed and individual cultures of
Escherichia coli, Pseudomonas aeruginosa and Vibrio spp.
[123]
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Table 3. Cont.
Source Type Activity Reference
Streptomyces sp. MAB36 Glycolipid
Antibacterial activity against Bacillus cereus, Enterococcus faecalis,
Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus aureus,
Staphylococcus epidermidis, Shigella dysenteriae and Shigella boydii
Antifungal activity against Candida albicans
[124]
Brachybacterium paraconglomeratum MSA21 Glycolipid
Antibacterial activity against Bacillus subtilis, Escherichia coli,
Enterococcus faecalis, Klebsiella pneumoniae, Micrococcus luteus,
Pseudomonas aeruginosa, Proteus mirabilis, Streptococcus sp.,
Staphylococcus aureus and Staphylococcus epidermidis
Antifungal activity against Candida albicans
[125]
Buttiauxella sp. M44 Glycolipid
Antibacterial activity against Escherichia coli, Salmonella enterica,
Bacillus cereus, Bacillus subtilis and Staphylococcus aureus
Antifungal activity against Candida albicans and Aspergillus niger
[126]
Staphylococcus lentus SZ2 Glycolipid
Antiadhesive activity against Vibrio harveyi and
Pseudomonas aeruginosa





Antibacterial activity against Staphyloccocus aureus,
Mycobacterium, Klebsiella peneumoniae and
Pseudomonas aeruginosa
Antifungal activity against Candida albicans
[71]
Halobacterium salinarum Lipopeptide
Antibacterial activity against Escherichia coli, Bacillus sps.,
Pseudomonas sp., Streptococcus sp. And Staphylococcus aureus
Antifungal activity against Aspergillus niger and Candida albicans
[127]
Nocardiopsis alba MSA10 Lipopeptide
Antibacterial activity against Enterococcus faecalis, Klebsiella
pneumoniae, Micrococcus luteus, Proteus mirabilis, Staphylococcus
aureus and Staphylococcus epidermidis
Antifungal activity against Candida albicans
[128]
Aneurinibacillus aneurinilyticus SBP-11 Lipopeptide
Antibacterial activity against Klebsiella pneumoniae, Escherichia
coli, Staphylococcus aureus, Pseudomonas aeruginosa, Bacillus
subtilis and Vibrio cholerae
[129]
Bacillus licheniformis NIOT-AMKV06 Lipopeptide
Antibacterial activity against Enterococcus faecalis, Klebsiella
pneumoniae, Micrococcus luteus, Proteus mirabilis, Salmonella typhi,
Shigella flexneri, Staphylococcus aureus and Vibrio cholera
[131]
Pontibacter korlensis strain SBK-47 Lipopeptide
Antibacterial activity against Streptococcus mutans, Micrococcus
luteus, Salmonella typhi and Klebsiella oxytoca
Antiadhesion potential against Bacillus subtilis, Staphylococcus
aureus, Salmonella typhi and Vibrio cholerae
[130]
Bacillus tequilensis CH Lipopeptide Antibiofilm activity against Escherichia coli andStreptococcus mutans [149]
Bacillus Amyloliquefaciens
anti-CA Lipopeptide
Antibiofilm activity against Pseudomonas aeruginosa and
Bacillus cereus [148]
Bacillus circulans Lipopeptide
Antiadhesive activity against Escherichia coli, Micrococcus flavus,
Serratia marcescens, Salmonella typhimurium, Proteus vulgaris,
Citrobacter freundii, Alcaligenes faecalis, and Klebsiella aerogenes
[147]
Aspergillus ustus MSF3 Glycolipoprotein
Antibacterial activity against Enterococcus faecalis, Escherichia
coli, Klebsiella pneumoniae, Micrococcus luteus, Pseudomonas
aeruginosa, Proteus mirabilis, Staphylococcus aureus, Staphylococcus
epidermidis and haemolytic Streptococcus







Antibacterial activity against Escherichia coli and
Pseudomonas aeruginosa
Antifungal activity against Candida albicans
[151]
Oceanobacillus iheyensis BK6 Extracellularpolysacchrides Antibiofilm activity against Staphylococcus aureus [152]
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6. Opportunities, Challenges and Future Perspectives
Currently, research on anti-infection materials for urinary catheters is still increasing,
and there is a growing demand for catheters with stronger antibiofilm and antiencrusta-
tion capabilities. Compared to the conservative strategy of optimizing existing products
(e.g., widening the internal lumen [1], replacing bulk silver with silver nanoparticles [4],
and redesign of micro/nano-scale surface topography [153]), the exploration of novel anti-
infection materials from marine resources has clearly become an exciting potential solution
to address some current limitations. Owing to the vast diversity of marine microorganisms,
a number of new bioactive molecules with antimicrobial, antiadhesive and antibiofilm
activities have been discovered that could be potentially combined with urinary catheters
to combat CAUTIs.
The antimicrobial strategy aims to endow urinary catheters with microbicidal or
microbiostatic properties to prevent the contact of microbes with the catheter surface or
inhibit microbial migration along the catheter, thus preventing biofilm formation and
encrustation. For short-term catheters, the use of antibiotics has proven to be the most
efficient and cost-effective strategy, whereas the application of conventional antibiotics (e.g.,
nitrofurazone) has been questioned due to the safety concerns and the presence of antibiotic
resistance. Despite attempts having been made to develop new antibiotics to solve this
problem, the difficulty in identifying novel and effective compounds has led to a slowdown
of research in this field. In recent decades, the isolation of microbes from previously
unexplored marine habitats has led to the discovery of a number of novel antimicrobial
compounds with new modes of action to combat the current antibiotic resistance threat.
Several of these have been proven to possess broad-spectrum antimicrobial activities
against a wide range of uropathogens, which could be potentially applied to urinary
catheters to eradicate CAUTIs. Technically, these antimicrobial molecules could be directly
deposited on the catheter surfaces or applied in coatings. Considering that CAUTIs may
be derived from both extraluminal and intraluminal routes, it would be ideal to endow
both surfaces with antimicrobial properties, despite extraluminal infections being clinically
more common. For example, commercial catheters have been conventionally impregnated
with antimicrobials, such as antibiotics, and function via a release model. However, this
is only a temporary solution for short-term catheterization, and microbial contamination
can resume once the antibiotics are removed. Given that the efficacy of antimicrobial
materials is often concentration dependent, a challenge in this type of catheter modification
strategy is to achieve and preserve adequate local delivery of the antimicrobials during
catheterization in vivo without inducing resistance and patient cytotoxicity. This could be
achieved by developing a novel release system with controlled release kinetics instead of
directly altering the drug loading. For example, hydrogel coatings, due to their lubricating
properties, have been widely applied in urinary catheters. Milo et al. [154] reported a
smart infection-responsive hydrogel coating for urinary catheters. The coating is a dual-
layered polymeric system consisting of a lower ‘reservoir’ layer of poly(vinyl alcohol)
(PVA) hydrogel (containing bacteriophage), capped by an upper layer of the pH-responsive
polymer. The upper layer swells when urinary pH is elevated due to P. mirabilis infection,
exposing the PVA reservoir layer to urine, resulting in the release of bacteriophage from
the coating to prevent the encrustation and blockage of urinary catheters. In this way, the
release of antimicrobials could be controlled in a smart way to prevent/retard CAUTIs and
associated complications. Researchers will need to further conduct thorough in vitro and
in vivo leaching and cytotoxicity studies to determine the optimum operational conditions
and identify any problematic side effects.
In long-term catheterization, extensive biofilms containing >5 × 109 viable cells/cm2
can be found on catheters and can be responsible for the persistence of the infections [155].
Moreover, the biofilms are often composed of multispecies consortia, which have been
reported to be more virulent and have a higher tolerance to antibiotics [7]. Therefore, in
addition to killing the uropathogens, attempts have also been made to combine catheter
surfaces with antiadhesive materials to retard the occurrence of CAUTIs. To date, only
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PTFE and hydrogel have entered clinical use, while their efficacy in resisting CAUTI
and encrustation is still controversial [4,17,33]. Other antiadhesive materials, such as
polyzwitterions, have recently emerged as promising candidates, although their instability
in long-term catheterization hinders practical application [1]. In this scenario, research on
marine microbes has led to the discovery of novel antiadhesive molecules with greater
activity and stability. For instance, marine microbial-derived antiadhesive materials, such
as biosurfactants and cyanobacterial extracellular polymers [59,156], can inhibit microbial
adhesion via multimechanisms. Currently, several biosurfactants have been reported
to influence both cell-to-cell and cell-to-surface interactions that can inhibit microbial
adhesion as well as disrupt biofilm formation [67,70,112]. Technically, biosurfactants could
be doped in coatings and act on microbial cells via a contact mode. These features may
aid in preventing biofilm formation and encrustation as well as extending the lifetime of
indwelling urinary catheters. Furthermore, they could be employed in combination with
other strategies (e.g., use of antimicrobial materials and micro/nano patterning) to achieve
synergistic effects.
In fact, although these marine microbial-derived molecules have shown potential
in combating CAUTI-related pathogens and/or biofilms, it should be noted that their
clinical effectiveness still needs to be verified in future. Currently, there has been a lack
of accomplished research in this area, and this paper provides a prospective proposal
for researchers. Currently, the most significant obstacles hindering the development of
marine microbial-derived products are supply issues. This is mainly due to difficulties
associated with the isolation and growth of producing microorganisms. In addition, for
marine microbial-derived biosurfactants, most of these materials are unidentified mixtures
of compounds, and the further pharmaceutical development of such mixtures is very
challenging. To date, the development of new chemical and physicochemical approaches
and tools has led to great advances in the isolation and structure elucidation of novel minor
marine secondary metabolites, which could not be isolated/detected in the past [54]. On
the other hand, urinary catheters are still considered as low-cost clinical care products,
although commercial ‘anti-infective’ catheters are usually priced two to five times higher
than standard catheters. Therefore, in addition to the cost of employing new materials, a
cost-effective coating technology should also be addressed.
7. Conclusions
Marine microorganisms can produce metabolites of varied chemical structures dis-
playing antimicrobial, antiadhesive and antibiofilm activities. These compounds present
enormous potential for the discovery of new agents to overcome the current challenges
associated with CAUTI. Owing to technical limitations in the past, bioactive compounds
derived from marine microorganisms have not yet progressed into clinical trials. However,
recent advances in oceanographic science and metabolome screening have led to a boost in
the discovery of new species and metabolic profiles as well as new molecules with potent
anti-infection activities against CAUTI-associated pathogens. Research efforts should be
applied to the exploration of marine microbes in the search for new bioactive compounds
for the development of novel anti-infection agents.
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